What product can lead to resistance in small strongyles of horses?

Fenbendazole is known to potentially lead to resistance in small strongyles of horses because of its mechanism of action and the way it interacts with the parasite population. When fenbendazole is used repeatedly or in an inadequate dosage, it can create selective pressure on the small strongyle population. This selective pressure can result in the survival of individuals that possess resistance traits, allowing them to reproduce and pass on those resistance genes to their offspring.

Over time, as resistance develops, the efficacy of fenbendazole decreases, meaning it may no longer effectively control the strongyle population within the horse. This situation is compounded if not enough time is allowed between treatments or if treatments are not strategically rotated with other classes of anthelmintics.

On the other hand, while pyrantel is also an anthelmintic used to treat strongyles, it has a different mode of action and its resistance profile might not be as pronounced as that of fenbendazole. Virus-based treatments, while they can be an important area of research, are not conventional deworming agents and do not contribute to resistance in the same context as traditional anthelmintics.

Overall, the concern about resistance specifically highlights the need for prudent use of fenbendazole in equine parasite